{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:46:33Z","timestamp":1786981593131,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11095-024-03745-8","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T12:03:10Z","timestamp":1730203390000},"page":"1951-1963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL\/6\u00a0J Mice as Potential Treatment for Multiple Sclerosis"],"prefix":"10.1007","volume":"41","author":[{"given":"Paraskevi","family":"Papakyriakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Balafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kostomitsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios M.","family":"Rekkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumlesh K.","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6844","authenticated-orcid":false,"given":"Georgia","family":"Valsami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"4","key":"3745_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31128\/AJGP-07-21-6103","volume":"51","author":"BS Travers","year":"2022","unstructured":"Travers BS, Tsang BK, Barton JL. Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis. Aust J Gen Pract. 2022;51(4):199\u2013206. https:\/\/doi.org\/10.31128\/AJGP-07-21-6103.","journal-title":"Aust J Gen Pract"},{"issue":"Suppl 6","key":"3745_CR2","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6s-s53","volume":"16","author":"A Doshi","year":"2016","unstructured":"Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(Suppl 6):s53\u20139. https:\/\/doi.org\/10.7861\/clinmedicine.16-6s-s53.","journal-title":"Clin Med (Lond)"},{"issue":"Suppl 1","key":"3745_CR3","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.4103\/0972-2327.164827","volume":"18","author":"P Shah","year":"2015","unstructured":"Shah P. Symptomatic management in multiple sclerosis. Ann Indian Acad Neurol. 2015;18(Suppl 1):S35-42. https:\/\/doi.org\/10.4103\/0972-2327.164827.","journal-title":"Ann Indian Acad Neurol"},{"issue":"11","key":"3745_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17460441.2019.1646244","volume":"14","author":"C Volpi","year":"2019","unstructured":"Volpi C, Orabona C, Macchiarulo A, Bianchi R, Puccetti P, Grohmann U. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opin Drug Discov. 2019;14(11):1199\u2013212. https:\/\/doi.org\/10.1080\/17460441.2019.1646244.","journal-title":"Expert Opin Drug Discov"},{"key":"3745_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/DDDT.S66398","volume":"8","author":"J Correale","year":"2014","unstructured":"Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I. Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod. Drug Des Devel Ther. 2014;8:859\u201367. https:\/\/doi.org\/10.2147\/DDDT.S66398.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"3745_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","volume":"51","author":"OJ David","year":"2012","unstructured":"David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15\u201328. https:\/\/doi.org\/10.2165\/11596550-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"3745_CR7","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.3390\/ijms22168370","volume":"22","author":"R Balasa","year":"2021","unstructured":"Balasa R, Barcutean L, Mosora O, Manu D. Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int J Mol Sci. 2021;22(16):8370. https:\/\/doi.org\/10.3390\/ijms22168370.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3745_CR8","first-page":"439","volume":"10","author":"JT Trevino","year":"2020","unstructured":"Trevino JT, Quispe RC, Khan F, Novak V. Non-Invasive Strategies for Nose-to-Brain Drug Delivery. J Clin Trials. 2020;10(7):439.","journal-title":"J Clin Trials"},{"issue":"11","key":"3745_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/pharmaceutics11110598","volume":"11","author":"JJ Lochhead","year":"2019","unstructured":"Lochhead JJ, Davis TP. Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration. Pharmaceutics. 2019;11(11):598. https:\/\/doi.org\/10.3390\/pharmaceutics11110598.","journal-title":"Pharmaceutics"},{"issue":"7","key":"3745_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328. https:\/\/doi.org\/10.1016\/j.addr.2011.11.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"3745_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1007\/s11095-010-0127-5","volume":"27","author":"YC Wong","year":"2010","unstructured":"Wong YC, Zuo Z. Intranasal delivery\u2013modification of drug metabolism and brain disposition. Pharm Res. 2010;27(7):1208\u201323. https:\/\/doi.org\/10.1007\/s11095-010-0127-5.","journal-title":"Pharm Res"},{"issue":"2","key":"3745_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/dmd.110.035907","volume":"39","author":"M Zollinger","year":"2011","unstructured":"Zollinger M, Gschwind HP, Jin Y, Sayer C, Z\u00e9cri F, Hartmann S. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos. 2011;39(2):199\u2013207. https:\/\/doi.org\/10.1124\/dmd.110.035907.","journal-title":"Drug Metab Dispos"},{"issue":"39","key":"3745_CR13","doi-asserted-by":"publisher","first-page":"15930","DOI":"10.1073\/pnas.1203534109","volume":"109","author":"RE Cannon","year":"2012","unstructured":"Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A. 2012;109(39):15930\u20135. https:\/\/doi.org\/10.1073\/pnas.1203534109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3745_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/pharmaceutics14081742","volume":"14","author":"P Papakyriakopoulou","year":"2022","unstructured":"Papakyriakopoulou P, Rekkas DM, Colombo G, Valsami G. Development and In Vitro-Ex Vivo Evaluation of Novel Polymeric Nasal Donepezil Films for Potential Use in Alzheimer\u2019s Disease Using Experimental Design. Pharmaceutics. 2022;14(8):1742. https:\/\/doi.org\/10.3390\/pharmaceutics14081742.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3745_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.30802\/AALAS-JAALAS-22-000091","volume":"62","author":"EG Balafas","year":"2023","unstructured":"Balafas EG, Papakyriakopoulou PI, Kostomitsopoulos NG, Valsami GN. Intranasal Administration of a Polymeric Biodegradable Film to C57BL\/6 Mice. J Am Assoc Lab Anim Sci. 2023;62(2):179\u201384. https:\/\/doi.org\/10.30802\/AALAS-JAALAS-22-000091.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"3745_CR16","doi-asserted-by":"publisher","first-page":"104463","DOI":"10.1016\/j.jddst.2023.104463","volume":"84","author":"P Papakyriakopoulou","year":"2023","unstructured":"Papakyriakopoulou P, Balafas E, Colombo C, Rekkas DM, Kostomitsopoulos N, Valsami G. Nose-to-Brain delivery of donepezil hydrochloride following administration of an HPMC-Me-\u03b2-CD-PEG400 nasal film in mice. J Drug Deliv Sci Technol. 2023;84:104463. https:\/\/doi.org\/10.1016\/j.jddst.2023.104463.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3745_CR17","doi-asserted-by":"publisher","first-page":"120994","DOI":"10.1016\/j.ijpharm.2021.120994","volume":"607","author":"F Laffleur","year":"2021","unstructured":"Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021;607:120994. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120994.","journal-title":"Int J Pharm"},{"issue":"4","key":"3745_CR18","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharmaceut Sci. 2010;99(4):1654\u201373. https:\/\/doi.org\/10.1002\/jps.21924.","journal-title":"J Pharmaceut Sci"},{"key":"3745_CR19","doi-asserted-by":"publisher","unstructured":"Gage GJ, Kipke DR, Shain W. Whole animal perfusion fixation for rodents, J Vis Exp 65. 2012; e3564. https:\/\/doi.org\/10.3791\/3564","DOI":"10.3791\/3564"},{"issue":"1","key":"3745_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3797\/scipharm.1408-08","volume":"83","author":"E Souri","year":"2014","unstructured":"Souri E, Zargarpoor M, Mottaghi S, Ahmadkhaniha R, Kebriaeezadeh A. A Stability-Indicating HPLC Method for the Determination of Fingolimod in Pharmaceutical Dosage Forms. Sci Pharm. 2014;83(1):85\u201393. https:\/\/doi.org\/10.3797\/scipharm.1408-08.","journal-title":"Sci Pharm"},{"key":"3745_CR21","doi-asserted-by":"publisher","first-page":"120827","DOI":"10.1016\/j.ijpharm.2021.120827","volume":"605","author":"L Tiozzo Fasiolo","year":"2021","unstructured":"Tiozzo Fasiolo L, Manniello MD, Banella S, Napoli L, Bortolotti F, Quarta E, Colombo P, Balafas E, Kostomitsopoulos N, Rekkas DM, Valsami G, Papakyriakopoulou P, Colombo G, Russo P. Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. Int J Pharm. 2021;605:120827. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120827.","journal-title":"Int J Pharm"},{"key":"3745_CR22","unstructured":"Gilenya, INN-fingolimod, Summary of products characteristics, EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf"},{"issue":"4","key":"3745_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0928-0987(99)00020-2","volume":"8","author":"M Wulff","year":"1999","unstructured":"Wulff M, Ald\u00e9n M. Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method. Eur J Pharm Sci. 1999;8(4):269\u201381. https:\/\/doi.org\/10.1016\/s0928-0987(99)00020-2.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3745_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1208\/s12248-019-0411-1","volume":"22","author":"P Zarmpi","year":"2020","unstructured":"Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties: Case Study-Hypromellose (HPMC). AAPS J. 2020;22(2):49. https:\/\/doi.org\/10.1208\/s12248-019-0411-1.","journal-title":"AAPS J"},{"issue":"3","key":"3745_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/pharmaceutics14030588","volume":"14","author":"PC Pires","year":"2022","unstructured":"Pires PC, Rodrigues M, Alves G, Santos AO. Strategies to Improve Drug Strength in Nasal Preparations for Brain Delivery of Low Aqueous Solubility Drugs. Pharmaceutics. 2022;14(3):588. https:\/\/doi.org\/10.3390\/pharmaceutics14030588.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3745_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","volume":"53","author":"SH Jeong","year":"2023","unstructured":"Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119\u201352. https:\/\/doi.org\/10.1007\/s40005-022-00589-5.","journal-title":"J Pharm Investig"},{"issue":"8","key":"3745_CR27","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1021\/acs.molpharmaceut.1c00366","volume":"18","author":"AR Clementino","year":"2021","unstructured":"Clementino AR, Pellegrini G, Banella S, Colombo G, Cant\u00f9 L, Sonvico F, Del Favero E. Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. Mol Pharm. 2021;18(8):3132\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00366.","journal-title":"Mol Pharm"},{"key":"3745_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","volume":"20","author":"DA Subramanian","year":"2022","unstructured":"Subramanian DA, Langer R, Traverso G. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. J Nanobiotechnol. 2022;20:362. https:\/\/doi.org\/10.1186\/s12951-022-01539-x.","journal-title":"J Nanobiotechnol"},{"key":"3745_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fchem.2018.00271","volume":"6","author":"TF Cova","year":"2018","unstructured":"Cova TF, Murtinho D, Pais AACC, Valente AJM. Combining Cellulose and Cyclodextrins: Fascinating Designs for Materials and Pharmaceutics. Front Chem. 2018;6:271. https:\/\/doi.org\/10.3389\/fchem.2018.00271.","journal-title":"Front Chem"},{"issue":"9","key":"3745_CR30","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1124\/dmd.105.009001","volume":"34","author":"GML Meno-Tetang","year":"2006","unstructured":"Meno-Tetang GML. Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses. Drug Metab Dispos. 2006;34(9):1480\u20137. https:\/\/doi.org\/10.1124\/dmd.105.009001.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"3745_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4155\/bio-2016-0308","volume":"9","author":"R Nirogi","year":"2017","unstructured":"Nirogi R, Padala NP, Ajjala DR, Boggavarapu RK, Kunduru P. Incurred sample reanalysis of fingolimod and fingolimod phosphate in blood: stability evaluation and application to a rat pharmacokinetic study. Bioanalysis. 2017;9(7):565\u201377. https:\/\/doi.org\/10.4155\/bio-2016-0308.","journal-title":"Bioanalysis"},{"key":"3745_CR32","unstructured":"Center for Drug Evaluation and Research [CDER]. Application number: 22\u2013527. Clinical harmacology and biopharmaceutics review(s) [online]. Available from URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022527orig1s000clinpharmr.pdf"},{"issue":"1","key":"3745_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1211\/0022357022511","volume":"56","author":"ES Kostewicz","year":"2004","unstructured":"Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56(1):43\u201351. https:\/\/doi.org\/10.1211\/0022357022511.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"3745_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1208\/s12248-015-9825-6","volume":"17","author":"DD Sun","year":"2015","unstructured":"Sun DD, Lee PI. Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating Formulations. AAPS J. 2015;17(6):1317\u201326. https:\/\/doi.org\/10.1208\/s12248-015-9825-6.","journal-title":"AAPS J"},{"issue":"9","key":"3745_CR35","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/molecules14093754","volume":"14","author":"Y Ozsoy","year":"2009","unstructured":"Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules. 2009;14(9):3754\u201379. https:\/\/doi.org\/10.3390\/molecules14093754.","journal-title":"Molecules"},{"issue":"8","key":"3745_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics13081180","volume":"13","author":"G Rassu","year":"2021","unstructured":"Rassu G, Sorrenti M, Catenacci L, Pavan B, Ferraro L, Gavini E, Bonferoni MC, Giunchedi P, Dalpiaz A. Versatile Nasal Application of Cyclodextrins: Excipients and\/or Actives? Pharmaceutics. 2021;13(8):1180. https:\/\/doi.org\/10.3390\/pharmaceutics13081180.","journal-title":"Pharmaceutics"},{"key":"3745_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","volume":"201","author":"G Rassu","year":"2015","unstructured":"Rassu G, Soddu E, Cossu M, Brundu A, Cerri G, Marchetti N, Ferraro L, Regan RF, Giunchedi P, Gavini E, Dalpiaz A. Solid microparticles based on chitosan or methyl-\u03b2-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release. 2015;201:68\u201377. https:\/\/doi.org\/10.1016\/j.jconrel.2015.01.025.","journal-title":"J Control Release"},{"issue":"5","key":"3745_CR38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/pharmaceutics15051409","volume":"15","author":"C Kaikousidis","year":"2023","unstructured":"Kaikousidis C, Papakyriakopoulou P, Dokoumetzidis A, Valsami G. Donepezil Brain and Blood Pharmacokinetic Modeling after Nasal Film and Oral Solution Administration in Mice. Pharmaceutics. 2023;15(5):1409. https:\/\/doi.org\/10.3390\/pharmaceutics15051409.","journal-title":"Pharmaceutics"},{"key":"3745_CR39","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.msard.2022.103518","volume":"59","author":"M Ghasemi-Kasman","year":"2022","unstructured":"Ghasemi-Kasman M, Nosratiyan N, Hashemian M, Ahmadian SR, Parsian H, Rostami-Mansoor S. Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm. Mult Scler Relat Disord. 2022;59:103518. https:\/\/doi.org\/10.1016\/j.msard.2022.103518.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"3745_CR40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1177\/0091270011427908","volume":"52","author":"C Boulton","year":"2013","unstructured":"Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study. J Clin Pharmacol. 2013;52(12):1879\u201390. https:\/\/doi.org\/10.1177\/0091270011427908.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3745_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/cjn.2015.325","volume":"43","author":"Y Lapierre","year":"2016","unstructured":"Lapierre Y, O\u2019Connor P, Devonshire V, Freedman MS, Kremenchutzky M, Yeung M, Schecter R. Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring. Can J Neurol Sci. 2016;43(2):278\u201383. https:\/\/doi.org\/10.1017\/cjn.2015.325.","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"3745_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","volume":"8","author":"B Barry","year":"2019","unstructured":"Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurol Ther. 2019;8(2):241\u201350. https:\/\/doi.org\/10.1007\/s40120-019-00160-9.","journal-title":"Neurol Ther"},{"key":"3745_CR43","doi-asserted-by":"publisher","first-page":"103278","DOI":"10.1016\/j.msard.2021.103278","volume":"56","author":"C Goncuoglu","year":"2021","unstructured":"Goncuoglu C, Tuncer A, Bayraktar-Ekincioglu A, Ayvacioglu Cagan C, Acar-Ozen P, Cakan M, Karabulut E, Karabudak R. Factors associated with fingolimod rebound: A single center real-life experience. Mult Scler Relat Disord. 2021;56:103278. https:\/\/doi.org\/10.1016\/j.msard.2021.103278.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"3745_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3109\/00498254.2011.598582","volume":"41","author":"Y Huh","year":"2011","unstructured":"Huh Y, Smith DE, Feng MR. Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica. 2011;41(11):972\u201387. https:\/\/doi.org\/10.3109\/00498254.2011.598582.","journal-title":"Xenobiotica"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03745-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:05:48Z","timestamp":1730455548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03745-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3745"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03745-8","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed. The experimental protocol of the study was approved by the Veterinary Authorities of Region of Athens, Greece (Ethical approval num. 300643\/Date of approval: 15\u201304\u20132021). The study was conducted in accordance with the ARRIVE guidelines and associated guidelines, EU Directive 2010\/63\/EU for animal experiments (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}